Citigroup Maintains Buy on Gilead Sciences, Raises Price Target to $165

Benzinga Newsdesk www.benzinga.com Positive 76.7%

Neg 0% Neu 0% Pos 76.7%

Citigroup analyst Geoff Meacham maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $156 to $165.